Companies
Who we bring together sets us apart
Companies
Our tenants span the life science sector, including therapeutics, diagnostics, medical devices, and research tools. They learn from and support each other, often forming partnerships.
Get to know our tenants, the
hardworking innovators at the
core of our community.
Tenant Spotlights
View all spotlightsLearn more about
their stories
Tenant Spotlight
Tenant Spotlight on Aikium: A Trillion Shots at Targeting Tangled Proteins
Aikium has essentially invented a new protein family. Called “SeqR” proteins, they are sequence specific binders that can be applied to different therapeutic needs such as cancer, neuro-inflammation, and some autoimmune disorders. Aikium is going after chemokine receptors, a subset of G-protein coupled receptors, a large class of molecules that have long proven difficult to target. By virtue of being on immune cells, they are front and center in cancer and immune-mediated diseases. Read post
Bakar Labs News
Bakar Labs Named a Finalist for 2024 Pantheon Awards
We’re excited to announce that California Life Sciences has selected us as a finalist for the 2024 Pantheon Awards! Want to support our mission? Vote for Bakar Labs in the academic/non-profit category (the deadline is October 15). Read post
Press ReleaseCompany News
NIH Awards ResVita Bio a $2M Phase II SBIR Grant for Continuous Protein Therapy for Netherton Syndrome
ResVita Bio is pioneering continuous protein therapy, delivered through a genetically engineered probiotic platform that temporarily colonizes the skin and continuously releases therapeutic proteins, such as LEKTI, to inhibit protease activity. This continuous delivery method ensures high levels of the therapeutic agent at the site of damage, restoring the integrity of the skin barrier. This represents a significant shift from traditional therapies, which may not provide sustained treatment at the site of the disease. Read post
BBH News
Ethical Innovation: ResVita Bio Uses L’Oréal’s Leading Skin Technology to Develop Revolutionary New Skin Treatments
ResVita Bio is not shy when it comes to innovation. But they have also managed to raise the bar for innovative cosmetic testing—without testing on animals. Read post
BBH News
Launch of Bakar ClimatEnginuity Hub Unites UC Berkeley Climate Tech Community
“Berkeley’s different from Las Vegas: what starts here does not end here,” said Dan Kammen, a UC Berkeley professor of energy and founding director of the Renewable and Appropriate Energy Laboratory, in his keynote address at the symposium to launch the Bakar ClimatEnginuity Hub (BCH), Berkeley’s innovation center and incubator for climate technology. BCH will accelerate the commercialization of new technologies, sending them forth to be adopted by humanity across the world as we adapt to and combat climate change. Read post
Press Release
ARIZ Precision Medicine Announces Grant of Key US Patent Covering Lead Cancer Drug
ARIZ has a proprietary ligand targeted nanoparticle drug delivery system designed to destroy cancer cells, without harming normal cells. ARIZ’s target a family of genes known as the PRDMs (Positive Regulatory Domain-containing Methyltransferases) that are genetic drivers that control cell growth, proliferation, survival and mobility. Studies show that alterations in the expression and activity of the PRDMs are among the first drivers in normal cells that lead to cancer cell formation. The PRDMs have been implicated in solid tumors such as breast, colon, gastric, liver, lung, melanoma, and prostate cancers, as well as in blood cancers such as leukemia, lymphoma and myeloma. Read post
BBH News
Bakar Climate Tech Incubator Recruiting Director of BD & Partnerships
The Director of Business Development and Partnerships of BCH will be responsible for developing highly innovative new programs and partnerships with local, national and international public and private entities to create and support a vibrant ecosystem that accelerates startup companies focused on the translation of scientific discoveries into solutions in the energy and climate tech marketplace. Read post
Company News
Minutia Receives Phase I SBIR Grant from National Institutes of Health
Minutia has secured a Phase I SBIR Grant from the NIH, supporting their mission to develop a functional cure for Type 1 diabetes. Read post
Golden Ticket News